www.feedkast.com
Open in
urlscan Pro
54.204.238.15
Public Scan
URL:
https://www.feedkast.com/feeds/759?customer_id=test_user
Submission Tags: falconsandbox
Submission: On February 17 via api from US — Scanned from DE
Submission Tags: falconsandbox
Submission: On February 17 via api from US — Scanned from DE
Summary
This website contacted 14 IPs
in 4 countries
across 11 domains to perform 39 HTTP transactions.
The main IP is 54.204.238.15, located in
Ashburn, United States and
belongs to AMAZON-AES, US.
The main domain is www.feedkast.com.
TLS certificate: Issued by R3 on January 10th 2023. Valid for: 3 months.
This is the only time www.feedkast.com was scanned on urlscan.io!
TLS certificate: Issued by R3 on January 10th 2023. Valid for: 3 months.
This is the only time www.feedkast.com was scanned on urlscan.io!
urlscan.io Verdict: No classification
Domain & IP information
| IP Address | AS Autonomous System | ||
|---|---|---|---|
| 10 | 54.204.238.15 54.204.238.15 | 14618 (AMAZON-AES) (AMAZON-AES) | |
| 1 | 2a00:1450:400... 2a00:1450:4001:831::200a | 15169 (GOOGLE) (GOOGLE) | |
| 2 | 2606:4700::68... 2606:4700::6811:180e | 13335 (CLOUDFLAR...) (CLOUDFLARENET) | |
| 3 | 2606:4700:e4:... 2606:4700:e4::ac40:a821 | 13335 (CLOUDFLAR...) (CLOUDFLARENET) | |
| 2 | 169.150.247.40 169.150.247.40 | 60068 (CDN77 ^_^) (CDN77 ^_^) | |
| 2 | 2a00:1450:400... 2a00:1450:400d:803::2008 | 15169 (GOOGLE) (GOOGLE) | |
| 6 | 52.216.112.53 52.216.112.53 | 16509 (AMAZON-02) (AMAZON-02) | |
| 1 | 2a02:26f0:11a... 2a02:26f0:11a::217:9a4b | 20940 (AKAMAI-ASN1) (AKAMAI-ASN1) | |
| 2 | 2a02:26f0:11a... 2a02:26f0:11a::217:9a58 | 20940 (AKAMAI-ASN1) (AKAMAI-ASN1) | |
| 2 | 2001:4860:480... 2001:4860:4802:34::178 | 15169 (GOOGLE) (GOOGLE) | |
| 1 | 2001:4860:480... 2001:4860:4802:34::36 | 15169 (GOOGLE) (GOOGLE) | |
| 5 | 151.101.66.137 151.101.66.137 | 54113 (FASTLY) (FASTLY) | |
| 1 | 162.247.241.14 162.247.241.14 | 23467 (NEWRELIC-...) (NEWRELIC-AS-1) | |
| 39 | 14 |
10
54.204.238.15
(Ashburn, United States)
ASN14618 (AMAZON-AES, US)
PTR: ec2-54-204-238-15.compute-1.amazonaws.com
ASN14618 (AMAZON-AES, US)
PTR: ec2-54-204-238-15.compute-1.amazonaws.com
| www.feedkast.com |
2
169.150.247.40
(Frankfurt am Main, Germany)
ASN60068 (CDN77 ^_^, GB)
PTR: unn-169-150-247-40.datapacket.com
ASN60068 (CDN77 ^_^, GB)
PTR: unn-169-150-247-40.datapacket.com
| plausible.io |
6
52.216.112.53
(Ashburn, United States)
ASN16509 (AMAZON-02, US)
PTR: s3-1.amazonaws.com
ASN16509 (AMAZON-02, US)
PTR: s3-1.amazonaws.com
| s3.amazonaws.com |
| Apex Domain Subdomains |
Transfer | |
|---|---|---|
| 10 |
feedkast.com
www.feedkast.com |
302 KB |
| 6 |
amazonaws.com
s3.amazonaws.com |
8 KB |
| 5 |
newrelic.com
js-agent.newrelic.com — Cisco Umbrella Rank: 341 |
10 KB |
| 3 |
google-analytics.com
www.google-analytics.com — Cisco Umbrella Rank: 35 region1.google-analytics.com — Cisco Umbrella Rank: 2506 |
20 KB |
| 3 |
typekit.net
p.typekit.net — Cisco Umbrella Rank: 577 use.typekit.net — Cisco Umbrella Rank: 440 |
36 KB |
| 3 |
fouanalytics.com
api.fouanalytics.com — Cisco Umbrella Rank: 6223 |
7 KB |
| 2 |
googletagmanager.com
www.googletagmanager.com — Cisco Umbrella Rank: 50 |
125 KB |
| 2 |
plausible.io
plausible.io — Cisco Umbrella Rank: 13968 |
2 KB |
| 2 |
cloudflare.com
cdnjs.cloudflare.com — Cisco Umbrella Rank: 196 |
108 KB |
| 1 |
nr-data.net
bam.nr-data.net — Cisco Umbrella Rank: 222 |
528 B |
| 1 |
googleapis.com
fonts.googleapis.com — Cisco Umbrella Rank: 43 |
1 KB |
| 39 | 11 |
| Domain | Requested by | |
|---|---|---|
| 10 | www.feedkast.com |
www.feedkast.com
|
| 6 | s3.amazonaws.com |
www.feedkast.com
|
| 5 | js-agent.newrelic.com |
www.feedkast.com
|
| 3 | api.fouanalytics.com |
www.feedkast.com
api.fouanalytics.com |
| 2 | www.google-analytics.com |
www.googletagmanager.com
www.google-analytics.com |
| 2 | use.typekit.net |
www.feedkast.com
|
| 2 | www.googletagmanager.com |
www.feedkast.com
|
| 2 | plausible.io |
www.feedkast.com
plausible.io |
| 2 | cdnjs.cloudflare.com |
www.feedkast.com
|
| 1 | bam.nr-data.net |
js-agent.newrelic.com
|
| 1 | region1.google-analytics.com |
www.googletagmanager.com
|
| 1 | p.typekit.net |
www.feedkast.com
|
| 1 | fonts.googleapis.com |
www.feedkast.com
|
| 39 | 13 |
This site contains links to these domains. Also see Links.
| Subject Issuer | Validity | Valid | |
|---|---|---|---|
| www.feedkast.com R3 |
2023-01-10 - 2023-04-10 |
3 months | crt.sh |
| upload.video.google.com GTS CA 1C3 |
2023-02-01 - 2023-04-26 |
3 months | crt.sh |
| sni.cloudflaressl.com Cloudflare Inc ECC CA-3 |
2022-08-03 - 2023-08-02 |
a year | crt.sh |
| plausible.io R3 |
2023-02-07 - 2023-05-08 |
3 months | crt.sh |
| *.google-analytics.com GTS CA 1C3 |
2023-02-01 - 2023-04-26 |
3 months | crt.sh |
| s3.amazonaws.com Amazon RSA 2048 M01 |
2022-12-06 - 2023-12-05 |
a year | crt.sh |
| use.typekit.net DigiCert TLS Hybrid ECC SHA384 2020 CA1 |
2022-09-14 - 2023-10-15 |
a year | crt.sh |
| js-agent.newrelic.com GlobalSign Atlas R3 DV TLS CA 2022 Q2 |
2022-07-10 - 2023-08-11 |
a year | crt.sh |
| *.nr-data.net DigiCert TLS RSA SHA256 2020 CA1 |
2022-11-18 - 2023-12-19 |
a year | crt.sh |
This page contains 1 frames:
Primary Page:
https://www.feedkast.com/feeds/759?customer_id=test_user
Frame ID: EDC92BF23654CB65805147A1FF3F4B83
Requests: 39 HTTP requests in this frame
Screenshot
Page Title
FeedkastDetected technologies
Ahoy (Analytics) Expand
Overall confidence: 100%
Detected patterns
Detected patterns
Font Awesome
(Font Scripts)
Expand
Overall confidence: 100%
Detected patterns
Detected patterns
- (?:F|f)o(?:n|r)t-?(?:A|a)wesome(?:.*?([0-9a-fA-F]{7,40}|[\d]+(?:.[\d]+(?:.[\d]+)?)?)|)
Google Analytics
(Analytics)
Expand
Overall confidence: 100%
Detected patterns
Detected patterns
- google-analytics\.com/(?:ga|urchin|analytics)\.js
Google Tag Manager
(Tag Managers)
Expand
Overall confidence: 100%
Detected patterns
Detected patterns
- googletagmanager\.com/gtm\.js
- googletagmanager\.com/gtag/js
Plausible
(Analytics)
Expand
Overall confidence: 100%
Detected patterns
Detected patterns
- plausible\.io/js/plausible\.js
Page Statistics
20 Outgoing links
These are links going to different origins than the main page.
URL: https://www.annalsofvascularsurgery.com/article/S0890-5096(23)00054-7/fulltext
Title: Safety and Efficacy of the Passeo-18 Lux Drug-Coated Balloon Catheter in Atherosclerotic Femoropopliteal Lesions: The multicenter BIOLUX P-IV China studyThe purpose of this trial was to assess the safety and effectiveness of a paclitaxel-coated balloon catheter in Chinese patients with de novo or non-stented restenotic femoropopliteal atherosclerotic lesions.The purpose of this trial was to assess the safety and effectiveness of a paclitaxel-coated balloon catheter in Chinese patients with de novo or non-stented restenotic femoropopliteal atherosclerotic lesions.
Title: Safety and Efficacy of the Passeo-18 Lux Drug-Coated Balloon Catheter in Atherosclerotic Femoropopliteal Lesions: The multicenter BIOLUX P-IV China studyThe purpose of this trial was to assess the safety and effectiveness of a paclitaxel-coated balloon catheter in Chinese patients with de novo or non-stented restenotic femoropopliteal atherosclerotic lesions.The purpose of this trial was to assess the safety and effectiveness of a paclitaxel-coated balloon catheter in Chinese patients with de novo or non-stented restenotic femoropopliteal atherosclerotic lesions.
Search URL Search Domain Scan URL
URL: https://www.internationaljournalofcardiology.com/article/S0167-5273(23)00237-1/fulltext
Title: Prognostic impact of cardiovascular polypharmacy on octogenarians with heart failure with preserved ejection fractionDrug treatments of heart failure with preserved ejection fraction (HFpEF) have a little clinical benefit, but cardiovascular polypharmacy (CP) trend is observed in elderly HFpEF. We investigated the impact of CP on octogenarian with HFpEF.Drug treatments of heart failure with preserved ejection fraction (HFpEF) have a little clinical benefit, but cardiovascular polypharmacy (CP) trend is observed in elderly HFpEF. We investigated the impact of CP on octogenarian with HFpEF.
Title: Prognostic impact of cardiovascular polypharmacy on octogenarians with heart failure with preserved ejection fractionDrug treatments of heart failure with preserved ejection fraction (HFpEF) have a little clinical benefit, but cardiovascular polypharmacy (CP) trend is observed in elderly HFpEF. We investigated the impact of CP on octogenarian with HFpEF.Drug treatments of heart failure with preserved ejection fraction (HFpEF) have a little clinical benefit, but cardiovascular polypharmacy (CP) trend is observed in elderly HFpEF. We investigated the impact of CP on octogenarian with HFpEF.
Search URL Search Domain Scan URL
URL: https://pubmed.ncbi.nlm.nih.gov/36791422/?fc=20230131153744&ff=20230215210713&v=2.17.9.post6+86293ac
Title: Apples and oranges in coronary artery disease diagnostics - PubMedApples and oranges in coronary artery disease diagnosticsApples and oranges in coronary artery disease diagnostics
Title: Apples and oranges in coronary artery disease diagnostics - PubMedApples and oranges in coronary artery disease diagnosticsApples and oranges in coronary artery disease diagnostics
Search URL Search Domain Scan URL
URL: https://www.cureus.com/articles/128899-a-case-of-multivessel-coronary-artery-disease-and-anomalous-origin-of-the-right-coronary-artery-with-a-malignant-course-presenting-with-non-exertional-chest-discomfort-and-brugada-phenocopy
Title: A Case of Multivessel Coronary Artery Disease and Anomalous Origin of the Right Coronary Artery With a Malignant Course Presenting With Non-exertional Chest Discomfort and Brugada PhenocopyCoronary artery anomalies (CAAs) are an uncommon cause of chest pain in the younger population. Misdiagnosis can be detrimental and lead to sudden cardiac deaths. We present a 62-year-old male with a past medical history significant for chest pain history with a workup in 2001 presumed to be non-cardiac in origin from bronchial asthma. He… Coronary artery anomalies (CAAs) are an uncommon cause of chest pain in the younger population. Misdiagnosis can be detrimental and lead to sudden cardiac deaths. We present a 62-year-old male with a past medical history significant for chest pain history with a workup in 2001 presumed to be non-cardiac in origin from bronchial asthma. He presented from a Micronesian Island for the evaluation of non-exertional chest discomfort. Further workup showed a Brugada type I pattern on ECG and ST wave depressions on anterolateral and inferior leads with associated AVR elevation on exercise stress testing. Further ischemic workup with coronary angiography revealed right dominant circulation with three-vessel coronary artery disease (CAD), including mid-left anterior descending (LAD) artery chronic total occlusion (CTO) with the right to left collaterals, left circumflex, and right coronary artery (RCA) with the accompanied anomalous origin of RCA. The patient underwent surgical correction of the anomalous RCA and coronary artery bypass grafting for the multi-vessel CAD. CAAs are usually found incidentally during ischemic workups similar to this case. Patients with CAAs can be managed conservatively with caution regarding physical activity. However, high-risk patients will warrant surgical treatment to avoid sudden cardiac death. The diagnosis of CAAs can be challenging and prone to misdiagnosis and maltreatment. It may be beneficial to pursue this in younger patients with ischemia-like symptoms. Further studies should be performed to identify the true incidence and guide medical practitioners regarding the risks, costs, and benefits of diagnosing and surgically treating CAAs in the general population.
Title: A Case of Multivessel Coronary Artery Disease and Anomalous Origin of the Right Coronary Artery With a Malignant Course Presenting With Non-exertional Chest Discomfort and Brugada PhenocopyCoronary artery anomalies (CAAs) are an uncommon cause of chest pain in the younger population. Misdiagnosis can be detrimental and lead to sudden cardiac deaths. We present a 62-year-old male with a past medical history significant for chest pain history with a workup in 2001 presumed to be non-cardiac in origin from bronchial asthma. He… Coronary artery anomalies (CAAs) are an uncommon cause of chest pain in the younger population. Misdiagnosis can be detrimental and lead to sudden cardiac deaths. We present a 62-year-old male with a past medical history significant for chest pain history with a workup in 2001 presumed to be non-cardiac in origin from bronchial asthma. He presented from a Micronesian Island for the evaluation of non-exertional chest discomfort. Further workup showed a Brugada type I pattern on ECG and ST wave depressions on anterolateral and inferior leads with associated AVR elevation on exercise stress testing. Further ischemic workup with coronary angiography revealed right dominant circulation with three-vessel coronary artery disease (CAD), including mid-left anterior descending (LAD) artery chronic total occlusion (CTO) with the right to left collaterals, left circumflex, and right coronary artery (RCA) with the accompanied anomalous origin of RCA. The patient underwent surgical correction of the anomalous RCA and coronary artery bypass grafting for the multi-vessel CAD. CAAs are usually found incidentally during ischemic workups similar to this case. Patients with CAAs can be managed conservatively with caution regarding physical activity. However, high-risk patients will warrant surgical treatment to avoid sudden cardiac death. The diagnosis of CAAs can be challenging and prone to misdiagnosis and maltreatment. It may be beneficial to pursue this in younger patients with ischemia-like symptoms. Further studies should be performed to identify the true incidence and guide medical practitioners regarding the risks, costs, and benefits of diagnosing and surgically treating CAAs in the general population.
Search URL Search Domain Scan URL
URL: https://mentalhealth.bmj.com/content/26/1/e300555
Title: Examining the Lancet Commission risk factors for dementia using Mendelian randomisationBackground Dementia incidence is increasing across the globe and currently there are no disease-modifying pharmaceutical treatments. The Lancet Commission on dementia identified 12 modifiable risk factors which explain 40% of dementia incidence. However, whether these associations are causal in nature is unclear. Objective To… Background Dementia incidence is increasing across the globe and currently there are no disease-modifying pharmaceutical treatments. The Lancet Commission on dementia identified 12 modifiable risk factors which explain 40% of dementia incidence. However, whether these associations are causal in nature is unclear. Objective To examine the modifiable risk factors for dementia as identified in the Lancet Commission review using Mendelian randomisation (MR) to establish if, based on genetic evidence, these associations with different dementia subtypes are causal in nature. Methods Publicly available genome-wide association study data were used for 10 risk factors and Alzheimer’s disease (AD), frontotemporal dementia and dementia with Lewy bodies. Two-sample MR using the inverse varianceweighted method was conducted to test for causal relationships. Weighted median MR and MR-Egger were used to test for pleiotropic effects. Results Genetic proxied risk for higher levels of smoking (OR: 0.80 (95% CI: 0.69; 0.92), p=0.002), obesity (OR: 0.87 (95% CI: 0.82; 0.92), p<0.001) and blood pressure (OR: 0.90 (95% CI: 0.82; 0.99), p=0.035) appeared to be protective against the risk of AD. Post hoc analyses indicated these associations had pleiotropic effects with the risk of coronary artery disease. Genetic proxied risk of educational attainment was found to be inconsistently associated with the risk of AD. Conclusions and implications Post hoc analysis indicated that the apparent protective effects of smoking, obesity and blood pressure were a result of survivor bias. The findings from this study did not support those presented by the Lancet Commission. Evidence from causal inference studies should be considered alongside evidence from epidemiological studies and incorporated into reviews of the literature. Data are available in a public, open access repository.
Title: Examining the Lancet Commission risk factors for dementia using Mendelian randomisationBackground Dementia incidence is increasing across the globe and currently there are no disease-modifying pharmaceutical treatments. The Lancet Commission on dementia identified 12 modifiable risk factors which explain 40% of dementia incidence. However, whether these associations are causal in nature is unclear. Objective To… Background Dementia incidence is increasing across the globe and currently there are no disease-modifying pharmaceutical treatments. The Lancet Commission on dementia identified 12 modifiable risk factors which explain 40% of dementia incidence. However, whether these associations are causal in nature is unclear. Objective To examine the modifiable risk factors for dementia as identified in the Lancet Commission review using Mendelian randomisation (MR) to establish if, based on genetic evidence, these associations with different dementia subtypes are causal in nature. Methods Publicly available genome-wide association study data were used for 10 risk factors and Alzheimer’s disease (AD), frontotemporal dementia and dementia with Lewy bodies. Two-sample MR using the inverse varianceweighted method was conducted to test for causal relationships. Weighted median MR and MR-Egger were used to test for pleiotropic effects. Results Genetic proxied risk for higher levels of smoking (OR: 0.80 (95% CI: 0.69; 0.92), p=0.002), obesity (OR: 0.87 (95% CI: 0.82; 0.92), p<0.001) and blood pressure (OR: 0.90 (95% CI: 0.82; 0.99), p=0.035) appeared to be protective against the risk of AD. Post hoc analyses indicated these associations had pleiotropic effects with the risk of coronary artery disease. Genetic proxied risk of educational attainment was found to be inconsistently associated with the risk of AD. Conclusions and implications Post hoc analysis indicated that the apparent protective effects of smoking, obesity and blood pressure were a result of survivor bias. The findings from this study did not support those presented by the Lancet Commission. Evidence from causal inference studies should be considered alongside evidence from epidemiological studies and incorporated into reviews of the literature. Data are available in a public, open access repository.
Search URL Search Domain Scan URL
URL: https://www.scielo.br/j/ramb/a/j3c9cJbG8vMLvvFxJvn3PBv/?lang=en
Title: Endofibrosis as a cause of peripheral artery disease: a comprehensive review and proposal of two novel algorithms for diagnosis and treatmentEndofibrosis is a rare condition affecting blood vessels, occurring mainly among young healthy athletes. This condition arises as progressive stenosis of the iliac arteries, which attenuates the blood circulation of the limb, thus leading to pain during movement. Iliac artery compression was first described in 1984 among professional cyclists11 Walder J… Endofibrosis is a rare condition affecting blood vessels, occurring mainly among young healthy athletes. This condition arises as progressive stenosis of the iliac arteries, which attenuates the blood circulation of the limb, thus leading to pain during movement. Iliac artery compression was first described in 1984 among professional cyclists11 Walder J, Mosimann F, Van Melle G, Mosimann R. A propos de l'endofibrose iliaque chez deux coureurs cyclistes. Helvet Chir Acta. 1985;51(6):793-5. PMID: 3972637. Some authors have reported that up to 10–20% of top athletes are affected22 Schep G, Schmikli SL, Bender MH, Mosterd WL, Hammacher ER, Wijn PF. Recognising vascular causes of leg complaints in endurance athletes. Part 1: validation of a decision algorithm. Int J Sports Med. 2002;23(5):313-21. https://doi.org/10.1055/s-2002-33141https://doi.org/10.1055/s-2002-33141... ,33 Feugier P, Chevalier J. Endofibrosis of the iliac arteries: an underestimated problem. Acta Chir Belg. 2004;104(6):635-40. https://doi.org/10.1080/00015458.2004.11679635https://doi.org/10.1080/00015458.2004.11... . Endofibrosis is one of the rare causes of peripheral artery disease, in which the exact prevalence is unknown, possessing no any accurate data.
Title: Endofibrosis as a cause of peripheral artery disease: a comprehensive review and proposal of two novel algorithms for diagnosis and treatmentEndofibrosis is a rare condition affecting blood vessels, occurring mainly among young healthy athletes. This condition arises as progressive stenosis of the iliac arteries, which attenuates the blood circulation of the limb, thus leading to pain during movement. Iliac artery compression was first described in 1984 among professional cyclists11 Walder J… Endofibrosis is a rare condition affecting blood vessels, occurring mainly among young healthy athletes. This condition arises as progressive stenosis of the iliac arteries, which attenuates the blood circulation of the limb, thus leading to pain during movement. Iliac artery compression was first described in 1984 among professional cyclists11 Walder J, Mosimann F, Van Melle G, Mosimann R. A propos de l'endofibrose iliaque chez deux coureurs cyclistes. Helvet Chir Acta. 1985;51(6):793-5. PMID: 3972637. Some authors have reported that up to 10–20% of top athletes are affected22 Schep G, Schmikli SL, Bender MH, Mosterd WL, Hammacher ER, Wijn PF. Recognising vascular causes of leg complaints in endurance athletes. Part 1: validation of a decision algorithm. Int J Sports Med. 2002;23(5):313-21. https://doi.org/10.1055/s-2002-33141https://doi.org/10.1055/s-2002-33141... ,33 Feugier P, Chevalier J. Endofibrosis of the iliac arteries: an underestimated problem. Acta Chir Belg. 2004;104(6):635-40. https://doi.org/10.1080/00015458.2004.11679635https://doi.org/10.1080/00015458.2004.11... . Endofibrosis is one of the rare causes of peripheral artery disease, in which the exact prevalence is unknown, possessing no any accurate data.
Search URL Search Domain Scan URL
URL: https://pubmed.ncbi.nlm.nih.gov/36789851/?fc=None&ff=20230215094716&v=2.17.9.post6+86293ac
Title: Clinical Characteristics and Outcomes Among People Living With HIV Undergoing Percutaneous Coronary Intervention: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program - PubMedBackground Clinical characteristics and outcomes in people living with HIV (PLWH) undergoing percutaneous coronary intervention (PCI) remain poorly described. We sought to compare real-world treatment of coronary artery disease, as well as patient and procedural factors and outcomes after PCI betwee …Background Clinical characteristics and outcomes in people living with HIV (PLWH) undergoing percutaneous coronary intervention (PCI) remain poorly described. We sought to compare real-world treatment of coronary artery disease, as well as patient and procedural factors and outcomes after PCI betwee …
Title: Clinical Characteristics and Outcomes Among People Living With HIV Undergoing Percutaneous Coronary Intervention: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program - PubMedBackground Clinical characteristics and outcomes in people living with HIV (PLWH) undergoing percutaneous coronary intervention (PCI) remain poorly described. We sought to compare real-world treatment of coronary artery disease, as well as patient and procedural factors and outcomes after PCI betwee …Background Clinical characteristics and outcomes in people living with HIV (PLWH) undergoing percutaneous coronary intervention (PCI) remain poorly described. We sought to compare real-world treatment of coronary artery disease, as well as patient and procedural factors and outcomes after PCI betwee …
Search URL Search Domain Scan URL
URL: https://ijbnpa.biomedcentral.com/articles/10.1186/s12966-023-01419-z
Title: Effectiveness of an intervention to reduce sedentary behaviour as a personalised secondary prevention strategy for patients with coronary artery disease: main outcomes of the SIT LESS randomised clinical trial - International Journal of Behavioral Nutrition and Physical ActivityA high sedentary time is associated with increased mortality risk. Previous studies indicate that replacement of sedentary time with light- and moderate-to-vigorous physical activity attenuates the risk for adverse outcomes and improves cardiovascular risk factors. Patients with cardiovascular disease are more sedentary compared to the… A high sedentary time is associated with increased mortality risk. Previous studies indicate that replacement of sedentary time with light- and moderate-to-vigorous physical activity attenuates the risk for adverse outcomes and improves cardiovascular risk factors. Patients with cardiovascular disease are more sedentary compared to the general population, while daily time spent sedentary remains high following contemporary cardiac rehabilitation programmes. This clinical trial investigated the effectiveness of a sedentary behaviour intervention as a personalised secondary prevention strategy (SIT LESS) on changes in sedentary time among patients with coronary artery disease participating in cardiac rehabilitation. Patients were randomised to usual care (n = 104) or SIT LESS (n = 108). Both groups received a comprehensive 12-week centre-based cardiac rehabilitation programme with face-to-face consultations and supervised exercise sessions, whereas SIT LESS participants additionally received a 12-week, nurse-delivered, hybrid behaviour change intervention in combination with a pocket-worn activity tracker connected to a smartphone application to continuously monitor sedentary time. Primary outcome was the change in device-based sedentary time between pre- to post-rehabilitation. Changes in sedentary time characteristics (prevalence of prolonged sedentary bouts and proportion of patients with sedentary time ≥ 9.5 h/day); time spent in light-intensity and moderate-to-vigorous physical activity; step count; quality of life; competencies for self-management; and cardiovascular risk score were assessed as secondary outcomes. Patients (77% male) were 63 ± 10 years and primarily diagnosed with myocardial infarction (78%). Sedentary time decreased in SIT LESS (− 1.6 [− 2.1 to − 1.1] hours/day) and controls (− 1.2 [ ─1.7 to − 0.8]), but between group differences did not reach statistical significance (─0.4 [─1.0 to 0.3]) hours/day). The post-rehabilitation proportion of patients with a sedentary time above the upper limit of normal (≥ 9.5 h/day) was significantly lower in SIT LESS versus controls (48% versus 72%, baseline-adjusted odds-ratio 0.4 (0.2–0.8)). No differences were observed in the other predefined secondary outcomes. Among patients with coronary artery disease participating in cardiac rehabilitation, SIT LESS did not induce significantly greater reductions in sedentary time compared to controls, but delivery was feasible and a reduced odds of a sedentary time ≥ 9.5 h/day was observed. Netherlands Trial Register: NL9263. Outcomes of the SIT LESS trial: changes in device-based sedentary time from pre-to post-cardiac rehabilitation (control group) and cardiac rehabilitation + SIT LESS (intervention group). SIT LESS reduced the odds of patients having a sedentary time >9.5 hours/day (upper limit of normal), although the absolute decrease in sedentary time did not significantly differ from controls. SIT LESS appears to be feasible, acceptable and potentially beneficial, but a larger cluster randomised trial is warranted to provide a more accurate estimate of its effects on sedentary time and clinical outcomes. CR: cardiac rehabilitation.
Title: Effectiveness of an intervention to reduce sedentary behaviour as a personalised secondary prevention strategy for patients with coronary artery disease: main outcomes of the SIT LESS randomised clinical trial - International Journal of Behavioral Nutrition and Physical ActivityA high sedentary time is associated with increased mortality risk. Previous studies indicate that replacement of sedentary time with light- and moderate-to-vigorous physical activity attenuates the risk for adverse outcomes and improves cardiovascular risk factors. Patients with cardiovascular disease are more sedentary compared to the… A high sedentary time is associated with increased mortality risk. Previous studies indicate that replacement of sedentary time with light- and moderate-to-vigorous physical activity attenuates the risk for adverse outcomes and improves cardiovascular risk factors. Patients with cardiovascular disease are more sedentary compared to the general population, while daily time spent sedentary remains high following contemporary cardiac rehabilitation programmes. This clinical trial investigated the effectiveness of a sedentary behaviour intervention as a personalised secondary prevention strategy (SIT LESS) on changes in sedentary time among patients with coronary artery disease participating in cardiac rehabilitation. Patients were randomised to usual care (n = 104) or SIT LESS (n = 108). Both groups received a comprehensive 12-week centre-based cardiac rehabilitation programme with face-to-face consultations and supervised exercise sessions, whereas SIT LESS participants additionally received a 12-week, nurse-delivered, hybrid behaviour change intervention in combination with a pocket-worn activity tracker connected to a smartphone application to continuously monitor sedentary time. Primary outcome was the change in device-based sedentary time between pre- to post-rehabilitation. Changes in sedentary time characteristics (prevalence of prolonged sedentary bouts and proportion of patients with sedentary time ≥ 9.5 h/day); time spent in light-intensity and moderate-to-vigorous physical activity; step count; quality of life; competencies for self-management; and cardiovascular risk score were assessed as secondary outcomes. Patients (77% male) were 63 ± 10 years and primarily diagnosed with myocardial infarction (78%). Sedentary time decreased in SIT LESS (− 1.6 [− 2.1 to − 1.1] hours/day) and controls (− 1.2 [ ─1.7 to − 0.8]), but between group differences did not reach statistical significance (─0.4 [─1.0 to 0.3]) hours/day). The post-rehabilitation proportion of patients with a sedentary time above the upper limit of normal (≥ 9.5 h/day) was significantly lower in SIT LESS versus controls (48% versus 72%, baseline-adjusted odds-ratio 0.4 (0.2–0.8)). No differences were observed in the other predefined secondary outcomes. Among patients with coronary artery disease participating in cardiac rehabilitation, SIT LESS did not induce significantly greater reductions in sedentary time compared to controls, but delivery was feasible and a reduced odds of a sedentary time ≥ 9.5 h/day was observed. Netherlands Trial Register: NL9263. Outcomes of the SIT LESS trial: changes in device-based sedentary time from pre-to post-cardiac rehabilitation (control group) and cardiac rehabilitation + SIT LESS (intervention group). SIT LESS reduced the odds of patients having a sedentary time >9.5 hours/day (upper limit of normal), although the absolute decrease in sedentary time did not significantly differ from controls. SIT LESS appears to be feasible, acceptable and potentially beneficial, but a larger cluster randomised trial is warranted to provide a more accurate estimate of its effects on sedentary time and clinical outcomes. CR: cardiac rehabilitation.
Search URL Search Domain Scan URL
URL: https://www.ajconline.org/article/S0002-9149(23)00032-2/fulltext
Title: Association of Anticoagulation and Major Adverse Limb Events After Index Peripheral Endovascular InterventionDual-antiplatelet therapy is commonly prescribed after endovascular intervention for peripheral artery disease. However, it is not known whether therapeutic anticoagulation affects outcomes after peripheral endovascular intervention. We sought to investigate whether therapeutic anticoagulation after peripheral endovascular intervention… Dual-antiplatelet therapy is commonly prescribed after endovascular intervention for peripheral artery disease. However, it is not known whether therapeutic anticoagulation affects outcomes after peripheral endovascular intervention. We sought to investigate whether therapeutic anticoagulation after peripheral endovascular intervention is associated with lower risk of major adverse limb events (MALEs) and all-cause mortality. We studied patients who underwent index endovascular intervention for peripheral artery disease in the Vascular Study Group of New England (2010 to 2018).
Title: Association of Anticoagulation and Major Adverse Limb Events After Index Peripheral Endovascular InterventionDual-antiplatelet therapy is commonly prescribed after endovascular intervention for peripheral artery disease. However, it is not known whether therapeutic anticoagulation affects outcomes after peripheral endovascular intervention. We sought to investigate whether therapeutic anticoagulation after peripheral endovascular intervention… Dual-antiplatelet therapy is commonly prescribed after endovascular intervention for peripheral artery disease. However, it is not known whether therapeutic anticoagulation affects outcomes after peripheral endovascular intervention. We sought to investigate whether therapeutic anticoagulation after peripheral endovascular intervention is associated with lower risk of major adverse limb events (MALEs) and all-cause mortality. We studied patients who underwent index endovascular intervention for peripheral artery disease in the Vascular Study Group of New England (2010 to 2018).
Search URL Search Domain Scan URL
URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0281371
Title: Patients with abdominal aortic aneurysms have reduced levels of microRNA 122-5p in circulating exosomesObjective There are currently no specific biomarkers to identify patients with abdominal aortic aneurysms (AAAs). Circulating exosomes contain microRNAs (miRNA) that are potential biomarkers for the presence of disease. This study aimed to characterize the exosomal miRNA expression profile of patients with AAAs in order to identify novel… Objective There are currently no specific biomarkers to identify patients with abdominal aortic aneurysms (AAAs). Circulating exosomes contain microRNAs (miRNA) that are potential biomarkers for the presence of disease. This study aimed to characterize the exosomal miRNA expression profile of patients with AAAs in order to identify novel biomarkers of disease. Methods Patients undergoing duplex ultrasound (US) or computed tomography (CT) for screening or surveillance of an AAA were screened to participate in the study. Cases with AAA were defined as having a max aortic diameter >3 cm. Circulating plasma exosomes were isolated using Cushioned-Density Gradient Ultracentrifugation and total RNA was extracted. Next Generation Sequencing was performed on the Illumina HiSeq4000 SE50. Differential miRNA expression analysis was performed using DESeq2 software with a Benjamini-Hochberg correction. MicroRNA expression profiles were validated by Quantitative Real-Time PCR. Results A total of 109 patients were screened to participate in the study. Eleven patients with AAA and 15 non-aneurysmal controls met study criteria and were enrolled. Ultrasound measured aortic diameter was significantly larger in the AAA group (mean maximum diameter 4.3 vs 2.0 cm, P = 6.45x10-6). More AAA patients had coronary artery disease (5/11 vs 1/15, P = 0.05) as compared to controls, but the groups did not differ significantly in the rates of peripheral arterial disease and chronic obstructive pulmonary disease. A total of 40 miRNAs were differentially expressed (P<0.05). Of these, 18 miRNAs were downregulated and 22 were upregulated in the AAA group compared to controls. After false discovery rate (FDR) adjustment, only miR-122-5p was expressed at significantly different levels in the AAA group compared to controls (fold change = 5.03 controls vs AAA; raw P = 1.8x10-5; FDR P = 0.02). Conclusion Plasma exosomes from AAA patients have significantly reduced levels of miRNA-122-5p compared to controls. This is a novel exosome-associated miRNA that warrants further investigation to determine its use as a diagnostic biomarker and potential implications in AAA pathogenesis.
Title: Patients with abdominal aortic aneurysms have reduced levels of microRNA 122-5p in circulating exosomesObjective There are currently no specific biomarkers to identify patients with abdominal aortic aneurysms (AAAs). Circulating exosomes contain microRNAs (miRNA) that are potential biomarkers for the presence of disease. This study aimed to characterize the exosomal miRNA expression profile of patients with AAAs in order to identify novel… Objective There are currently no specific biomarkers to identify patients with abdominal aortic aneurysms (AAAs). Circulating exosomes contain microRNAs (miRNA) that are potential biomarkers for the presence of disease. This study aimed to characterize the exosomal miRNA expression profile of patients with AAAs in order to identify novel biomarkers of disease. Methods Patients undergoing duplex ultrasound (US) or computed tomography (CT) for screening or surveillance of an AAA were screened to participate in the study. Cases with AAA were defined as having a max aortic diameter >3 cm. Circulating plasma exosomes were isolated using Cushioned-Density Gradient Ultracentrifugation and total RNA was extracted. Next Generation Sequencing was performed on the Illumina HiSeq4000 SE50. Differential miRNA expression analysis was performed using DESeq2 software with a Benjamini-Hochberg correction. MicroRNA expression profiles were validated by Quantitative Real-Time PCR. Results A total of 109 patients were screened to participate in the study. Eleven patients with AAA and 15 non-aneurysmal controls met study criteria and were enrolled. Ultrasound measured aortic diameter was significantly larger in the AAA group (mean maximum diameter 4.3 vs 2.0 cm, P = 6.45x10-6). More AAA patients had coronary artery disease (5/11 vs 1/15, P = 0.05) as compared to controls, but the groups did not differ significantly in the rates of peripheral arterial disease and chronic obstructive pulmonary disease. A total of 40 miRNAs were differentially expressed (P<0.05). Of these, 18 miRNAs were downregulated and 22 were upregulated in the AAA group compared to controls. After false discovery rate (FDR) adjustment, only miR-122-5p was expressed at significantly different levels in the AAA group compared to controls (fold change = 5.03 controls vs AAA; raw P = 1.8x10-5; FDR P = 0.02). Conclusion Plasma exosomes from AAA patients have significantly reduced levels of miRNA-122-5p compared to controls. This is a novel exosome-associated miRNA that warrants further investigation to determine its use as a diagnostic biomarker and potential implications in AAA pathogenesis.
Search URL Search Domain Scan URL
URL: https://link.springer.com/article/10.1007/s12055-022-01457-5
Title: Surgical management of drug-eluting stent associated coronary artery aneurysms: a case series - Indian Journal of Thoracic and Cardiovascular SurgeryDrug-eluting stents (DES) have been introduced to counter the in-stent restenosis associated with bare metal stents. However, the mechanism of action of DEDrug-eluting stents (DES) have been introduced to counter the in-stent restenosis associated with bare metal stents. However, the mechanism of action of DE
Title: Surgical management of drug-eluting stent associated coronary artery aneurysms: a case series - Indian Journal of Thoracic and Cardiovascular SurgeryDrug-eluting stents (DES) have been introduced to counter the in-stent restenosis associated with bare metal stents. However, the mechanism of action of DEDrug-eluting stents (DES) have been introduced to counter the in-stent restenosis associated with bare metal stents. However, the mechanism of action of DE
Search URL Search Domain Scan URL
URL: https://link.springer.com/article/10.1007/s12055-022-01466-4
Title: Total arterial revascularization in a case of dextrocardia with situs inversus - Indian Journal of Thoracic and Cardiovascular SurgeryDextrocardia and situs inversus with coronary artery disease poses unique challenges with respect to presentation and diagnosis. From a surgical point of vDextrocardia and situs inversus with coronary artery disease poses unique challenges with respect to presentation and diagnosis. From a surgical point of v
Title: Total arterial revascularization in a case of dextrocardia with situs inversus - Indian Journal of Thoracic and Cardiovascular SurgeryDextrocardia and situs inversus with coronary artery disease poses unique challenges with respect to presentation and diagnosis. From a surgical point of vDextrocardia and situs inversus with coronary artery disease poses unique challenges with respect to presentation and diagnosis. From a surgical point of v
Search URL Search Domain Scan URL
URL: https://link.springer.com/article/10.1007/s12055-022-01454-8
Title: Surgical revascularization strategies of CAD involving dual left anterior descending artery - Indian Journal of Thoracic and Cardiovascular SurgeryDual left anterior descending artery (LAD) is not an uncommon coronary artery anomaly. Preoperative identification of this anomaly in patients with coronarDual left anterior descending artery (LAD) is not an uncommon coronary artery anomaly. Preoperative identification of this anomaly in patients with coronar
Title: Surgical revascularization strategies of CAD involving dual left anterior descending artery - Indian Journal of Thoracic and Cardiovascular SurgeryDual left anterior descending artery (LAD) is not an uncommon coronary artery anomaly. Preoperative identification of this anomaly in patients with coronarDual left anterior descending artery (LAD) is not an uncommon coronary artery anomaly. Preoperative identification of this anomaly in patients with coronar
Search URL Search Domain Scan URL
URL: https://link.springer.com/article/10.1007/s00259-023-06125-3
Title: The prognostic value of CZT SPECT myocardial blood flow (MBF) quantification in patients with ischemia and no obstructive coronary artery disease (INOCA): a pilot study - European Journal of Nuclear Medicine and Molecular ImagingDespite the demonstrated adverse outcome, it is difficult to early identify the risks for patients with ischemia and no obstructive coronary artery diseaseDespite the demonstrated adverse outcome, it is difficult to early identify the risks for patients with ischemia and no obstructive coronary artery disease
Title: The prognostic value of CZT SPECT myocardial blood flow (MBF) quantification in patients with ischemia and no obstructive coronary artery disease (INOCA): a pilot study - European Journal of Nuclear Medicine and Molecular ImagingDespite the demonstrated adverse outcome, it is difficult to early identify the risks for patients with ischemia and no obstructive coronary artery diseaseDespite the demonstrated adverse outcome, it is difficult to early identify the risks for patients with ischemia and no obstructive coronary artery disease
Search URL Search Domain Scan URL
URL: https://www.mediasphera.ru/issues/arkhiv-patologii/2023/1/1000419552023011029
Title: Причины смерти в Московской области по данным медицинских свидетельств о смерти<h3>ЦЕЛЬ ИССЛЕДОВАНИЯ</h3><p>Определение ведущих причин смерти на основании данных первичных медицинских свидетельств о смерти (МСС) в зависимости от места смерти.</p><h3>МАТЕРИАЛ И МЕТОДЫ</h3><p>Из электронной базы данных Главного управления ЗАГС Московской области (система ЕГР… <h3>ЦЕЛЬ ИССЛЕДОВАНИЯ</h3><p>Определение ведущих причин смерти на основании данных первичных медицинских свидетельств о смерти (МСС) в зависимости от места смерти.</p><h3>МАТЕРИАЛ И МЕТОДЫ</h3><p>Из электронной базы данных Главного управления ЗАГС Московской области (система ЕГР ЗАГС) за 2021 г. отобраны все случаи, в которых в качестве первоначальной причины смерти (ППС) указаны заболевания (исключены все коды внешних причин, травм и отравлений). Всего 109 126 случаев, в стационаре умерли 50,6%, дома — 34%, в другом месте — 16,4%. ГБУЗ МО Бюро судебно-медицинской экспертизы (БСМЭ) выдано 45,2% МСС. С учетом частоты применения кодов МКБ, клинической близости отдельных кодов сформировано 20 групп, что составило 90,1% смертей от заболеваний.</p><h3>РЕЗУЛЬТАТЫ</h3><p>Частота регистрации отдельных групп причин смерти в значительной степени зависит от места смерти. Установлено 5 ведущих групп причин смерти: 1) в целом от COVID-19 умерли 23,55% человек, от хронических форм ишемической болезни сердца (ХИБС-1) без постинфарктного кардиосклероза, аневризмы и ишемической кардиомиопатии (КМП) — 14,5%, от энцефалопатии неопределенной (ЭН) — 11,4%, от злокачественных новообразований (ЗНО) — 11,3%, от острого нарушения мозгового кровообращения (ОНМК) — 6,2%; 2) в стационаре от COVID-19 — 45%, от ОНМК — 10%, от ЗНО — 8,3%; от ХИБС-1 — 7,1%, от ХИБС с инфарктом миокарда в анамнезе/ишемической КМП — 2,7%; 3) дома от ХИБС-1 — 21,8%, от ЭН — 21,5%, от ЗНО — 15,5%, от заболеваний, ассоциированных с алкоголем — 3,3% и кистой мозга — 3,3%; 4) в другом месте от ХИБС-1 — 22,7%, от ЭН — 21,6%, от ЗНО — 12%, от других форм острой ИБС — 5,4%, от заболеваний, ассоциированных с алкоголем, — 4,8%. Острый ИМ занял 6-е ранговое место среди смертей в целом — 2,7%. ППС также связана с местом выдачи МСС — 90% МСС с указанием ЭН и «другие дегенеративные болезни нервной системы» в качестве причины смерти выданы БСМЭ. Ни в одном МСС, выданном БСМЭ, не было таких ППС, как «старость» или «киста мозга».</p><h3>ЗАКЛЮЧЕНИЕ</h3><p>Нозологическая структура причин смерти и вынесение отдельных кодов МКБ в МСС в качестве ППС значительно варьируют в зависимости от места смерти и выдачи МСС. Причины нуждаются в дальнейшем уточнении. Зарегистрировано применение кодов, не разрешенных к применению.</p>
Title: Причины смерти в Московской области по данным медицинских свидетельств о смерти<h3>ЦЕЛЬ ИССЛЕДОВАНИЯ</h3><p>Определение ведущих причин смерти на основании данных первичных медицинских свидетельств о смерти (МСС) в зависимости от места смерти.</p><h3>МАТЕРИАЛ И МЕТОДЫ</h3><p>Из электронной базы данных Главного управления ЗАГС Московской области (система ЕГР… <h3>ЦЕЛЬ ИССЛЕДОВАНИЯ</h3><p>Определение ведущих причин смерти на основании данных первичных медицинских свидетельств о смерти (МСС) в зависимости от места смерти.</p><h3>МАТЕРИАЛ И МЕТОДЫ</h3><p>Из электронной базы данных Главного управления ЗАГС Московской области (система ЕГР ЗАГС) за 2021 г. отобраны все случаи, в которых в качестве первоначальной причины смерти (ППС) указаны заболевания (исключены все коды внешних причин, травм и отравлений). Всего 109 126 случаев, в стационаре умерли 50,6%, дома — 34%, в другом месте — 16,4%. ГБУЗ МО Бюро судебно-медицинской экспертизы (БСМЭ) выдано 45,2% МСС. С учетом частоты применения кодов МКБ, клинической близости отдельных кодов сформировано 20 групп, что составило 90,1% смертей от заболеваний.</p><h3>РЕЗУЛЬТАТЫ</h3><p>Частота регистрации отдельных групп причин смерти в значительной степени зависит от места смерти. Установлено 5 ведущих групп причин смерти: 1) в целом от COVID-19 умерли 23,55% человек, от хронических форм ишемической болезни сердца (ХИБС-1) без постинфарктного кардиосклероза, аневризмы и ишемической кардиомиопатии (КМП) — 14,5%, от энцефалопатии неопределенной (ЭН) — 11,4%, от злокачественных новообразований (ЗНО) — 11,3%, от острого нарушения мозгового кровообращения (ОНМК) — 6,2%; 2) в стационаре от COVID-19 — 45%, от ОНМК — 10%, от ЗНО — 8,3%; от ХИБС-1 — 7,1%, от ХИБС с инфарктом миокарда в анамнезе/ишемической КМП — 2,7%; 3) дома от ХИБС-1 — 21,8%, от ЭН — 21,5%, от ЗНО — 15,5%, от заболеваний, ассоциированных с алкоголем — 3,3% и кистой мозга — 3,3%; 4) в другом месте от ХИБС-1 — 22,7%, от ЭН — 21,6%, от ЗНО — 12%, от других форм острой ИБС — 5,4%, от заболеваний, ассоциированных с алкоголем, — 4,8%. Острый ИМ занял 6-е ранговое место среди смертей в целом — 2,7%. ППС также связана с местом выдачи МСС — 90% МСС с указанием ЭН и «другие дегенеративные болезни нервной системы» в качестве причины смерти выданы БСМЭ. Ни в одном МСС, выданном БСМЭ, не было таких ППС, как «старость» или «киста мозга».</p><h3>ЗАКЛЮЧЕНИЕ</h3><p>Нозологическая структура причин смерти и вынесение отдельных кодов МКБ в МСС в качестве ППС значительно варьируют в зависимости от места смерти и выдачи МСС. Причины нуждаются в дальнейшем уточнении. Зарегистрировано применение кодов, не разрешенных к применению.</p>
Search URL Search Domain Scan URL
URL: https://www.nature.com/articles/s41598-023-29347-9
Title: How scan parameter choice affects deep learning-based coronary artery disease assessment from computed tomography - Scientific ReportsRecently, algorithms capable of assessing the severity of Coronary Artery Disease (CAD) in form of the Coronary Artery Disease-Reporting and Data System (CAD-RADS) grade from Coronary Computed Tomography Angiography (CCTA) scans using Deep Learning (DL) were proposed. Before considering to apply these algorithms in clinical practice… Recently, algorithms capable of assessing the severity of Coronary Artery Disease (CAD) in form of the Coronary Artery Disease-Reporting and Data System (CAD-RADS) grade from Coronary Computed Tomography Angiography (CCTA) scans using Deep Learning (DL) were proposed. Before considering to apply these algorithms in clinical practice, their robustness regarding different commonly used Computed Tomography (CT)-specific image formation parameters—including denoising strength, slab combination, and reconstruction kernel—needs to be evaluated. For this study, we reconstructed a data set of 500 patient CCTA scans under seven image formation parameter configurations. We select one default configuration and evaluate how varying individual parameters impacts the performance and stability of a typical algorithm for automated CAD assessment from CCTA. This algorithm consists of multiple preprocessing and a DL prediction step. We evaluate the influence of the parameter changes on the entire pipeline and additionally on only the DL step by propagating the centerline extraction results of the default configuration to all others. We consider the standard deviation of the CAD severity prediction grade difference between the default and variation configurations to assess the stability w.r.t. parameter changes. For the full pipeline we observe slight instability (± 0.226 CAD-RADS) for all variations. Predictions are more stable with centerlines propagated from the default to the variation configurations (± 0.122 CAD-RADS), especially for differing denoising strengths (± 0.046 CAD-RADS). However, stacking slabs with sharp boundaries instead of mixing slabs in overlapping regions (called true stack ± 0.313 CAD-RADS) and increasing the sharpness of the reconstruction kernel (± 0.150 CAD-RADS) leads to unstable predictions. Regarding the clinically relevant tasks of excluding CAD (called rule-out; AUC default 0.957, min 0.937) and excluding obstructive CAD (called hold-out; AUC default 0.971, min 0.964) the performance remains on a high level for all variations. Concluding, an influence of reconstruction parameters on the predictions is observed. Especially, scans reconstructed with the true stack parameter need to be treated with caution when using a DL-based method. Also, reconstruction kernels which are underrepresented in the training data increase the prediction uncertainty.
Title: How scan parameter choice affects deep learning-based coronary artery disease assessment from computed tomography - Scientific ReportsRecently, algorithms capable of assessing the severity of Coronary Artery Disease (CAD) in form of the Coronary Artery Disease-Reporting and Data System (CAD-RADS) grade from Coronary Computed Tomography Angiography (CCTA) scans using Deep Learning (DL) were proposed. Before considering to apply these algorithms in clinical practice… Recently, algorithms capable of assessing the severity of Coronary Artery Disease (CAD) in form of the Coronary Artery Disease-Reporting and Data System (CAD-RADS) grade from Coronary Computed Tomography Angiography (CCTA) scans using Deep Learning (DL) were proposed. Before considering to apply these algorithms in clinical practice, their robustness regarding different commonly used Computed Tomography (CT)-specific image formation parameters—including denoising strength, slab combination, and reconstruction kernel—needs to be evaluated. For this study, we reconstructed a data set of 500 patient CCTA scans under seven image formation parameter configurations. We select one default configuration and evaluate how varying individual parameters impacts the performance and stability of a typical algorithm for automated CAD assessment from CCTA. This algorithm consists of multiple preprocessing and a DL prediction step. We evaluate the influence of the parameter changes on the entire pipeline and additionally on only the DL step by propagating the centerline extraction results of the default configuration to all others. We consider the standard deviation of the CAD severity prediction grade difference between the default and variation configurations to assess the stability w.r.t. parameter changes. For the full pipeline we observe slight instability (± 0.226 CAD-RADS) for all variations. Predictions are more stable with centerlines propagated from the default to the variation configurations (± 0.122 CAD-RADS), especially for differing denoising strengths (± 0.046 CAD-RADS). However, stacking slabs with sharp boundaries instead of mixing slabs in overlapping regions (called true stack ± 0.313 CAD-RADS) and increasing the sharpness of the reconstruction kernel (± 0.150 CAD-RADS) leads to unstable predictions. Regarding the clinically relevant tasks of excluding CAD (called rule-out; AUC default 0.957, min 0.937) and excluding obstructive CAD (called hold-out; AUC default 0.971, min 0.964) the performance remains on a high level for all variations. Concluding, an influence of reconstruction parameters on the predictions is observed. Especially, scans reconstructed with the true stack parameter need to be treated with caution when using a DL-based method. Also, reconstruction kernels which are underrepresented in the training data increase the prediction uncertainty.
Search URL Search Domain Scan URL
URL: https://www.nature.com/articles/s41598-023-29006-z
Title: A multicenter, randomized, open-labelled, non-inferiority trial of sustained-release sarpogrelate versus clopidogrel after femoropopliteal artery intervention - Scientific ReportsOptimal antiplatelet therapy after endovascular therapy (EVT) for peripheral artery disease is controversial. This trial aimed to evaluate whether sarpogrelate plus aspirin was non-inferior for preventing early restenosis after femoropopliteal (FP) EVT compared to clopidogrel plus aspirin. In this open-label, prospective randomized trial, 272… Optimal antiplatelet therapy after endovascular therapy (EVT) for peripheral artery disease is controversial. This trial aimed to evaluate whether sarpogrelate plus aspirin was non-inferior for preventing early restenosis after femoropopliteal (FP) EVT compared to clopidogrel plus aspirin. In this open-label, prospective randomized trial, 272 patients were enrolled after successful EVT for FP lesions. Patients in each group received aspirin 100 mg and clopidogrel 75 mg or sarpogrelate 300 mg orally once per day for 6 months. The primary outcome was target lesion restenosis at 6 months, tested for noninferiority. Patient characteristics and EVT patterns were similar, except for increased inflow procedures in the sarpogrelate group and increased outflow procedures in the clopidogrel group. The sarpogrelate group showed a tendency of less restenosis at 6 months than the clopidogrel group (13.0% vs. 19.1%, difference 6.1 percentage points, 95% CI for noninferiority − 0.047 to 0.169). Secondary endpoints related to safety outcomes were rare in both groups. Risks of target lesion restenosis of the two intervention arm were uniform across most major subgroups except for those with coronary artery disease. In conclusion, Sarpogrelate plus aspirin is non-inferior to clopidogrel plus aspirin in preventing early restenosis after FP EVT. Larger multi-ethnic trials are required to generalize these findings. Trial registration: National Institutes of Health Clinical Trials Registry (ClinicalTrials.gov identifier: NCT02959606; 09/11/2016).
Title: A multicenter, randomized, open-labelled, non-inferiority trial of sustained-release sarpogrelate versus clopidogrel after femoropopliteal artery intervention - Scientific ReportsOptimal antiplatelet therapy after endovascular therapy (EVT) for peripheral artery disease is controversial. This trial aimed to evaluate whether sarpogrelate plus aspirin was non-inferior for preventing early restenosis after femoropopliteal (FP) EVT compared to clopidogrel plus aspirin. In this open-label, prospective randomized trial, 272… Optimal antiplatelet therapy after endovascular therapy (EVT) for peripheral artery disease is controversial. This trial aimed to evaluate whether sarpogrelate plus aspirin was non-inferior for preventing early restenosis after femoropopliteal (FP) EVT compared to clopidogrel plus aspirin. In this open-label, prospective randomized trial, 272 patients were enrolled after successful EVT for FP lesions. Patients in each group received aspirin 100 mg and clopidogrel 75 mg or sarpogrelate 300 mg orally once per day for 6 months. The primary outcome was target lesion restenosis at 6 months, tested for noninferiority. Patient characteristics and EVT patterns were similar, except for increased inflow procedures in the sarpogrelate group and increased outflow procedures in the clopidogrel group. The sarpogrelate group showed a tendency of less restenosis at 6 months than the clopidogrel group (13.0% vs. 19.1%, difference 6.1 percentage points, 95% CI for noninferiority − 0.047 to 0.169). Secondary endpoints related to safety outcomes were rare in both groups. Risks of target lesion restenosis of the two intervention arm were uniform across most major subgroups except for those with coronary artery disease. In conclusion, Sarpogrelate plus aspirin is non-inferior to clopidogrel plus aspirin in preventing early restenosis after FP EVT. Larger multi-ethnic trials are required to generalize these findings. Trial registration: National Institutes of Health Clinical Trials Registry (ClinicalTrials.gov identifier: NCT02959606; 09/11/2016).
Search URL Search Domain Scan URL
URL: https://www.nature.com/articles/s41569-023-00839-5
Title: The role of aldehyde dehydrogenase 2 in cardiovascular disease - Nature Reviews CardiologyAldehyde dehydrogenase 2 (ALDH2) is a mitochondrial enzyme involved in the detoxification of alcohol-derived acetaldehyde and endogenous aldehydes. The inactivating ALDH2 rs671 polymorphism, present in up to 8% of the global population and in up to 50% of the East Asian population, is associated with increased risk of cardiovascular… Aldehyde dehydrogenase 2 (ALDH2) is a mitochondrial enzyme involved in the detoxification of alcohol-derived acetaldehyde and endogenous aldehydes. The inactivating ALDH2 rs671 polymorphism, present in up to 8% of the global population and in up to 50% of the East Asian population, is associated with increased risk of cardiovascular conditions such as coronary artery disease, alcohol-induced cardiac dysfunction, pulmonary arterial hypertension, heart failure and drug-induced cardiotoxicity. Although numerous studies have attributed an accumulation of aldehydes (secondary to alcohol consumption, ischaemia or elevated oxidative stress) to an increased risk of cardiovascular disease (CVD), this accumulation alone does not explain the emerging protective role of ALDH2 rs671 against ageing-related cardiac dysfunction and the development of aortic aneurysm or dissection. ALDH2 can also modulate risk factors associated with atherosclerosis, such as cholesterol biosynthesis and HDL biogenesis in hepatocytes and foam cell formation and efferocytosis in macrophages, via non-enzymatic pathways. In this Review, we summarize the basic biology and the clinical relevance of the enzymatic and non-enzymatic, tissue-specific roles of ALDH2 in CVD, and discuss the future directions in the research and development of therapeutic strategies targeting ALDH2. A thorough understanding of the complex roles of ALDH2 in CVD will improve the diagnosis, management and prognosis of patients with CVD who harbour the ALDH2 rs671 polymorphism. Aldehyde dehydrogenase 2 (ALDH2), a key enzyme for the detoxification of alcohol-derived acetaldehyde, has been implicated in the pathogenesis of various types of cardiovascular disease. In this Review, Xu and colleagues present the latest evidence showing a link between the inactivating ALDH2 rs671 polymorphism and an increased or decreased risk of cardiovascular disease such as coronary artery disease.
Title: The role of aldehyde dehydrogenase 2 in cardiovascular disease - Nature Reviews CardiologyAldehyde dehydrogenase 2 (ALDH2) is a mitochondrial enzyme involved in the detoxification of alcohol-derived acetaldehyde and endogenous aldehydes. The inactivating ALDH2 rs671 polymorphism, present in up to 8% of the global population and in up to 50% of the East Asian population, is associated with increased risk of cardiovascular… Aldehyde dehydrogenase 2 (ALDH2) is a mitochondrial enzyme involved in the detoxification of alcohol-derived acetaldehyde and endogenous aldehydes. The inactivating ALDH2 rs671 polymorphism, present in up to 8% of the global population and in up to 50% of the East Asian population, is associated with increased risk of cardiovascular conditions such as coronary artery disease, alcohol-induced cardiac dysfunction, pulmonary arterial hypertension, heart failure and drug-induced cardiotoxicity. Although numerous studies have attributed an accumulation of aldehydes (secondary to alcohol consumption, ischaemia or elevated oxidative stress) to an increased risk of cardiovascular disease (CVD), this accumulation alone does not explain the emerging protective role of ALDH2 rs671 against ageing-related cardiac dysfunction and the development of aortic aneurysm or dissection. ALDH2 can also modulate risk factors associated with atherosclerosis, such as cholesterol biosynthesis and HDL biogenesis in hepatocytes and foam cell formation and efferocytosis in macrophages, via non-enzymatic pathways. In this Review, we summarize the basic biology and the clinical relevance of the enzymatic and non-enzymatic, tissue-specific roles of ALDH2 in CVD, and discuss the future directions in the research and development of therapeutic strategies targeting ALDH2. A thorough understanding of the complex roles of ALDH2 in CVD will improve the diagnosis, management and prognosis of patients with CVD who harbour the ALDH2 rs671 polymorphism. Aldehyde dehydrogenase 2 (ALDH2), a key enzyme for the detoxification of alcohol-derived acetaldehyde, has been implicated in the pathogenesis of various types of cardiovascular disease. In this Review, Xu and colleagues present the latest evidence showing a link between the inactivating ALDH2 rs671 polymorphism and an increased or decreased risk of cardiovascular disease such as coronary artery disease.
Search URL Search Domain Scan URL
URL: https://www.jvascsurg.org/article/S0741-5214(23)00311-7/fulltext
Title: Most Privately Insured Patients Do Not Receive Federally Recommended Abdominal Aortic Aneurysm ScreeningSince 2005, the United States Preventative Services Task Force (USPSTF) has recommended abdominal aortic aneurysm (AAA) ultrasound screening for 65- to 75-year-old male ever-smokers. Integrated health systems such as Kaiser Permanente and the Veterans Affairs (VA) healthcare system report 74-79% adherence, but compliance rates… Since 2005, the United States Preventative Services Task Force (USPSTF) has recommended abdominal aortic aneurysm (AAA) ultrasound screening for 65- to 75-year-old male ever-smokers. Integrated health systems such as Kaiser Permanente and the Veterans Affairs (VA) healthcare system report 74-79% adherence, but compliance rates in the private sector are unknown.
Title: Most Privately Insured Patients Do Not Receive Federally Recommended Abdominal Aortic Aneurysm ScreeningSince 2005, the United States Preventative Services Task Force (USPSTF) has recommended abdominal aortic aneurysm (AAA) ultrasound screening for 65- to 75-year-old male ever-smokers. Integrated health systems such as Kaiser Permanente and the Veterans Affairs (VA) healthcare system report 74-79% adherence, but compliance rates… Since 2005, the United States Preventative Services Task Force (USPSTF) has recommended abdominal aortic aneurysm (AAA) ultrasound screening for 65- to 75-year-old male ever-smokers. Integrated health systems such as Kaiser Permanente and the Veterans Affairs (VA) healthcare system report 74-79% adherence, but compliance rates in the private sector are unknown.
Search URL Search Domain Scan URL
URL: https://heart.bmj.com/content/early/2023/01/03/heartjnl-2022-321702
Title: Prevalence, outcomes and costs of a contemporary, multinational population with heart failureObjective Digital healthcare systems could provide insights into the global prevalence of heart failure (HF). We designed the CardioRenal and Metabolic disease (CaReMe) HF study to estimate the prevalence, key clinical adverse outcomes and costs of HF across 11 countries. Methods Individual level data from a contemporary cohort of 6 29 624… Objective Digital healthcare systems could provide insights into the global prevalence of heart failure (HF). We designed the CardioRenal and Metabolic disease (CaReMe) HF study to estimate the prevalence, key clinical adverse outcomes and costs of HF across 11 countries. Methods Individual level data from a contemporary cohort of 6 29 624 patients with diagnosed HF was obtained from digital healthcare systems in participating countries using a prespecified, common study plan, and summarised using a random effects meta-analysis. A broad definition of HF (any registered HF diagnosis) and a strict definition (history of hospitalisation for HF) were used. Event rates were reported per 100 patient years. Cumulative hospital care costs per patient were calculated for a period of up to 5 years. Results The prevalence of HF was 2.01% (95% CI 1.65 to 2.36) and 1.05% (0.85 to 1.25) according to the broad and strict definitions, respectively. In patients with HF (broad definition), mean age was 75.2 years (95% CI 74.0 to 76.4), 48.8% (40.9–56.8%) had ischaemic heart disease and 34.5% (29.4–39.6%) had diabetes. In 51 442 patients with a recorded ejection fraction (EF), 39.1% (30.3–47.8%) had a reduced, 18.8% (13.5–24.0%) had a mildly reduced and 42.1% (31.5–52.8%) had a preserved left ventricular EF. In 1 69 518 patients with recorded estimated glomerular filtration rate, 49% had chronic kidney disease (CKD) stages III–V. Event rates were highest for cardiorenal disease (HF or CKD) and all cause mortality (19.3 (95% CI 11.3 to 27.1) and 13.1 (11.1 to 15.1), respectively), and lower for myocardial infarction, stroke and peripheral artery disease. Hospital care costs were highest for cardiorenal diseases. Conclusions We estimate that 1–2% of the contemporary adult population has HF. These individuals are at significant risk of adverse outcomes and associated costs, predominantly driven by hospitalisations for HF or CKD. There is considerable public health potential in understanding the contemporary burden of HF and the importance of optimising its management. No data are available. The data sources used in the present are all underlying local, ethical and privacy restrictions for data transfer abroad or into public domain, limiting data availability on request. Therefore, the data that support the findings of this study are not available on request.
Title: Prevalence, outcomes and costs of a contemporary, multinational population with heart failureObjective Digital healthcare systems could provide insights into the global prevalence of heart failure (HF). We designed the CardioRenal and Metabolic disease (CaReMe) HF study to estimate the prevalence, key clinical adverse outcomes and costs of HF across 11 countries. Methods Individual level data from a contemporary cohort of 6 29 624… Objective Digital healthcare systems could provide insights into the global prevalence of heart failure (HF). We designed the CardioRenal and Metabolic disease (CaReMe) HF study to estimate the prevalence, key clinical adverse outcomes and costs of HF across 11 countries. Methods Individual level data from a contemporary cohort of 6 29 624 patients with diagnosed HF was obtained from digital healthcare systems in participating countries using a prespecified, common study plan, and summarised using a random effects meta-analysis. A broad definition of HF (any registered HF diagnosis) and a strict definition (history of hospitalisation for HF) were used. Event rates were reported per 100 patient years. Cumulative hospital care costs per patient were calculated for a period of up to 5 years. Results The prevalence of HF was 2.01% (95% CI 1.65 to 2.36) and 1.05% (0.85 to 1.25) according to the broad and strict definitions, respectively. In patients with HF (broad definition), mean age was 75.2 years (95% CI 74.0 to 76.4), 48.8% (40.9–56.8%) had ischaemic heart disease and 34.5% (29.4–39.6%) had diabetes. In 51 442 patients with a recorded ejection fraction (EF), 39.1% (30.3–47.8%) had a reduced, 18.8% (13.5–24.0%) had a mildly reduced and 42.1% (31.5–52.8%) had a preserved left ventricular EF. In 1 69 518 patients with recorded estimated glomerular filtration rate, 49% had chronic kidney disease (CKD) stages III–V. Event rates were highest for cardiorenal disease (HF or CKD) and all cause mortality (19.3 (95% CI 11.3 to 27.1) and 13.1 (11.1 to 15.1), respectively), and lower for myocardial infarction, stroke and peripheral artery disease. Hospital care costs were highest for cardiorenal diseases. Conclusions We estimate that 1–2% of the contemporary adult population has HF. These individuals are at significant risk of adverse outcomes and associated costs, predominantly driven by hospitalisations for HF or CKD. There is considerable public health potential in understanding the contemporary burden of HF and the importance of optimising its management. No data are available. The data sources used in the present are all underlying local, ethical and privacy restrictions for data transfer abroad or into public domain, limiting data availability on request. Therefore, the data that support the findings of this study are not available on request.
Search URL Search Domain Scan URL
Redirected requests
There were HTTP redirect chains for the following requests:
39 HTTP transactions
| Method Protocol |
Resource Path |
Size x-fer |
Type MIME-Type |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
GET H/1.1 |
Primary Request
759
www.feedkast.com/feeds/ |
118 KB 119 KB |
Document
text/html |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H2 |
css
fonts.googleapis.com/ |
6 KB 1 KB |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H/1.1 |
application-d738b947ac4c9ac6c3feb119c63fac27fd362cc5fe6efb39103a6a7271b9484e.css
www.feedkast.com/assets/ |
69 KB 15 KB |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H/1.1 |
application-05850f6905a47bafb883e32f675b48fc023aaa818d1229239c7de0c2965f57aa.js
www.feedkast.com/assets/ |
265 KB 80 KB |
Script
application/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H2 |
video.min.js
cdnjs.cloudflare.com/ajax/libs/video.js/7.7.4/ |
457 KB 103 KB |
Script
application/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H2 |
postscribe.min.js
cdnjs.cloudflare.com/ajax/libs/postscribe/2.0.5/ |
17 KB 6 KB |
Script
application/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H2 |
init-1772vuh2fst8a9l4y3lr.js
api.fouanalytics.com/api/ |
467 B 882 B |
Script
text/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H2 |
plausible.js
plausible.io/js/ |
1 KB 1 KB |
Script
application/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H2 |
js
www.googletagmanager.com/gtag/ |
218 KB 76 KB |
Script
application/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H/1.1 |
black-72072c81a59474808b8f989661301a3cab1a1eb6546a02eab426bc202aef3db4.svg
www.feedkast.com/assets/logos/full/ |
6 KB 6 KB |
Image
image/svg+xml |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H/1.1 |
coloured-2259c5e31b1c14cf349b8c4fd7fb9a24caa2afc018ce9768c9359794ae68d490.svg
www.feedkast.com/assets/logos/icon/ |
2 KB 3 KB |
Image
image/svg+xml |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H/1.1 |
favicon.png
s3.amazonaws.com/watzan-bss/sources/614882/pictures/ |
1 KB 2 KB |
Image
image/png |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H/1.1 |
data
s3.amazonaws.com/watzan-bss/sources/1213375/pictures/ |
597 B 953 B |
Image
image/png |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H/1.1 |
favicon.ico
s3.amazonaws.com/watzan-bss/sources/628/pictures/ |
1 KB 1 KB |
Image
image/vnd.microsoft.icon |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H/1.1 |
favicon.ico
s3.amazonaws.com/watzan-bss/sources/15252/pictures/ |
1 KB 1 KB |
Image
image/vnd.microsoft.icon |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H/1.1 |
favicon-16x16.bfd0e25c74.png
s3.amazonaws.com/watzan-bss/sources/2312/pictures/ |
589 B 945 B |
Image
image/png |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H/1.1 |
favicon.ico
s3.amazonaws.com/watzan-bss/sources/128449/pictures/ |
1 KB 1 KB |
Image
image/vnd.microsoft.icon |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H/1.1 |
arrow-up-white-18edfd23350f5cd87229da2954598af04241e45dd5ca50d87cee435edbec6547.svg
www.feedkast.com/assets/icons/ |
413 B 666 B |
Image
image/svg+xml |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H/1.1 |
close-a9e330874fc76c9eb079b55821f817ad3243a0e4f18ef771cce5195329544738.svg
www.feedkast.com/assets/icons/ |
432 B 685 B |
Image
image/svg+xml |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H2 |
p.css
p.typekit.net/ |
5 B 181 B |
Stylesheet
text/css |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H2 |
gtm.js
www.googletagmanager.com/ |
128 KB 49 KB |
Script
application/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET BLOB |
a8d04c2a-ec00-4f42-8156-e1089d2b1019
https://www.feedkast.com/ |
31 B 0 |
Other
application/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
POST H/1.1 |
945
www.feedkast.com/load_advertisement/ |
0 925 B |
XHR
text/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H/1.1 |
arrow-down.svg
www.feedkast.com/assets/icons/ |
369 B 1 KB |
Image
image/svg+xml |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H2 |
l
use.typekit.net/af/ef2129/00000000000000003b9b387c/27/ |
18 KB 18 KB |
Font
application/font-woff2 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H/1.1 |
fontawesome-webfont-2adefcbc041e7d18fcf2d417879dc5a09997aa64d675b7a3c4b6ce33da13f3fe.woff2
www.feedkast.com/assets/ |
75 KB 76 KB |
Font
application/font-woff2 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H2 |
l
use.typekit.net/af/403911/00000000000000003b9b3880/27/ |
18 KB 18 KB |
Font
application/font-woff2 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
POST H2 |
event
plausible.io/api/ |
2 B 477 B |
XHR
text/plain |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H2 |
pp.js
api.fouanalytics.com/s/ |
15 KB 6 KB |
Script
text/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H2 |
analytics.js
www.google-analytics.com/ |
49 KB 20 KB |
Script
text/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
POST H2 |
collect
region1.google-analytics.com/g/ |
0 255 B |
Ping
text/plain |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
POST H2 |
collect
www.google-analytics.com/j/ |
3 B 209 B |
XHR
text/plain |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H2 |
692.215647de-1223.js
js-agent.newrelic.com/ |
2 KB 2 KB |
Script
application/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H2 |
779.215647de-1223.js
js-agent.newrelic.com/ |
8 KB 4 KB |
Script
application/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H2 |
823.215647de-1223.js
js-agent.newrelic.com/ |
3 KB 2 KB |
Script
application/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H2 |
785.215647de-1223.js
js-agent.newrelic.com/ |
5 KB 2 KB |
Script
application/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H2 |
325.215647de-1223.js
js-agent.newrelic.com/ |
1 KB 766 B |
Script
application/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
GET H/1.1 |
9af4428e91
bam.nr-data.net/1/ |
49 B 528 B |
Script
text/javascript |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
POST H3 |
x
api.fouanalytics.com/api/ |
0 460 B |
XHR
text/plain |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
General
Request headers
Response headers
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Verdicts & Comments Add Verdict or Comment
45 JavaScript Global Variables
These are the non-standard "global" variables defined on the window object. These can be helpful in identifying possible client-side frameworks and code.
boolean| credentialless object| oncontentvisibilityautostatechange object| NREUM object| webpackChunkNRBA object| newrelic object| NRBA function| Dotdotdot function| tns function| $ function| jQuery object| jQuery112403539511089143248 object| Turbolinks number| googleLT_ object| google function| google_exportSymbol function| google_exportProperty function| validate_input function| selectLists function| sendSelf function| open_modal function| close_modal number| infiniteScrollInterval number| checkSpinnerInterval function| bindInfiniteScroll function| calcSticky function| truncate object| vttjs function| WebVTT function| videojs function| postscribe function| gtag object| dataLayer object| ads function| doubleClickAdClickEventListener function| plausible number| tnsId function| __$PP object| google_tag_manager object| google_tag_data string| GoogleAnalyticsObject function| ga function| onYouTubeIframeAPIReady object| gaGlobal object| gaplugins object| gaData7 Cookies
Cookies are little pieces of information stored in the browser of a user. Whenever a user visits the site again, he will also send his cookie values, thus allowing the website to re-identify him even if he changed locations. This is how permanent logins work.
| Domain/Path | Expires | Name / Value |
|---|---|---|
| www.feedkast.com/ | Name: ahoy_visitor Value: 2c42a728-7ef1-48cc-8dd6-26df53babdbd |
|
| www.feedkast.com/ | Name: ahoy_visit Value: e265387c-7a74-48ea-8743-b37aecbc41b3 |
|
| www.feedkast.com/ | Name: _AnalyZer_session Value: MjQrUHhhOW1sMG1IU1JyZkpZN00rMFNpd1dlZ2gxZ2I1ZURDTmxsNlBEaDlNR2xJK1VTekdqR2U0VTkwMEJpa0tWTlZoVU02aWF4Qm1nL1ZvVUFLWGEwVDZMcTJBUkFrMnhZa3lBeUVERDV1YlhITUpKVHhSTDd0V0E5K1NLdWVKV2EyU2M4UytOYzBsa3AwdjdiZ3FpeGxvNk1ISUhhdExEajc3bURQVzJ1U0p3cWlqYjdaTWdsb0twM2wxTEhtLS1FVGNyU1V4ODZFZlFMNEsrejRhclB3PT0%3D--64d816ccc6affb2eee6f0584e56b89d7b785d774 |
|
| .feedkast.com/ | Name: _ga_DZLKTPHXFN Value: GS1.1.1676661482.1.0.1676661482.0.0.0 |
|
| .feedkast.com/ | Name: _ga Value: GA1.2.1816982588.1676661482 |
|
| .feedkast.com/ | Name: _gid Value: GA1.2.1889542117.1676661482 |
|
| .feedkast.com/ | Name: _gat_UA-172762791-1 Value: 1 |
Security Headers
This page lists any security headers set by the main page. If you want to understand what these mean and how to use them, head on over to this page
| Header | Value |
|---|---|
| Strict-Transport-Security | max-age=15552000 |
| X-Content-Type-Options | nosniff |
| X-Frame-Options | SAMEORIGIN |
| X-Xss-Protection | 1; mode=block |
Indicators
This is a term in the security industry to describe indicators such as IPs, Domains, Hashes, etc. This does not imply that any of these indicate malicious activity.
api.fouanalytics.com
bam.nr-data.net
cdnjs.cloudflare.com
fonts.googleapis.com
js-agent.newrelic.com
p.typekit.net
plausible.io
region1.google-analytics.com
s3.amazonaws.com
use.typekit.net
www.feedkast.com
www.google-analytics.com
www.googletagmanager.com
151.101.66.137
162.247.241.14
169.150.247.40
2001:4860:4802:34::178
2001:4860:4802:34::36
2606:4700::6811:180e
2606:4700:e4::ac40:a821
2a00:1450:4001:831::200a
2a00:1450:400d:803::2008
2a02:26f0:11a::217:9a4b
2a02:26f0:11a::217:9a58
52.216.112.53
54.204.238.15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